DA Davidson analyst Peter Heckmann raised the firm’s price target on Paysign (PAYS) to $8 from $7 and keeps a Buy rating on the shares. Last week, Paysign announced the company had been awarded 132 established plasma donation centers through an expansion of a relationship with a major plasma collection company, and the firm believes this will increase the company’s total plasma locations to 613 centers, a 27% increase over the 484 locations served at the end of Q1, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- PaySign’s Strong Growth Potential and Strategic Positioning in Healthcare: A Buy Rating by Gary Prestopino
- Paysign participates in a conference call with DA Davidson
- PaySign’s Strong Growth Potential and Strategic Positioning Earns Buy Rating from Analyst
- Paysign awarded 132 plasma donation centers
- Paysign price target raised to $6-$7 range from $5 at Barrington